Form 4: Stoke Therapeutics Director Sells Shares for Tax Obligations

Stoke Therapeutics Director Edward M. Kaye MD reported the sale of common stock to cover tax withholding liabilities following the vesting of restricted stock units.

Summary

• Edward M. Kaye MD, a Director at Stoke Therapeutics, Inc. (STOK), reported changes in his beneficial ownership of the company's common stock.
• On December 1, 2025, 4,317 restricted stock units (RSUs) vested, resulting in the acquisition of 4,317 shares of common stock at a price of $0.
• Following this acquisition, Edward M. Kaye MD beneficially owned 53,441 shares of common stock.
• To satisfy tax withholding liabilities related to the RSU vesting, Edward M. Kaye MD sold a total of 2,136 shares of common stock over two days.
• On December 2, 2025, 661 shares were sold at a weighted average price of $29.562 (ranging from $28.93 to $29.92) and 405 shares were sold at a weighted average price of $30.1419 (ranging from $29.93 to $30.63).
• On December 3, 2025, 419 shares were sold at a weighted average price of $30.338 (ranging from $29.81 to $30.805) and 651 shares were sold at a weighted average price of $30.8477 (ranging from $30.815 to $31.17).
• After all reported transactions, Edward M. Kaye MD's beneficial ownership stands at 51,305 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine, non-discretionary sales by a director to cover tax obligations arising from RSU vesting, rather than a discretionary sale indicating a change in confidence in the company's prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine tax-related sales by a director, not indicative of a change in company fundamentals or management's discretionary view of the stock's value.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The reported transactions are routine, non-discretionary sales by a director to cover tax liabilities associated with the vesting of restricted stock units. Such transactions do not typically reflect a change in the insider's view of the company's future prospects or fundamental value, and therefore, do not warrant a change in investment recommendation based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership